Clinical trials: Parkinson Disease(PD)
Parkinson Disease
Transcutaneous Afferent Patterned Stimulation (TAPS) for Reduction of Parkinson's Disease (PD) Related Action Tremor
Demonstrate safety and efficacy of TAPS delivered by a Cala device as a treatment for action tremor in subjects with Parkinson's disease hand tremor
- Trial name
- NCT05012579
- Testing
- Cala Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cala Health, Inc.
Healthy Volunteers (HV), Parkinson's Disease (PD)
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD).
- Trial name
- NCT07310264
- Testing
- VT-5006
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Vertero Therapeutics
Advanced Parkinson's Disease
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.
- Trial name
- ROADMAP (NCT01536015)
- Testing
- Rotigotine
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- UCB Pharma
Parkinson Disease
Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients
The objective of this trial is to evaluate non-inferiority of pramipexole Extended release to Immediate release at 18 weeks on the primary efficacy endpoint (Unified Parkinson's Disease Rating Scale II+III) in Chinese PD patients…
- Trial name
- NCT01191944
- Testing
- pramipexole immediate release tablet, pramipexole extended release tablet
- Where
- 20 sites in China
- Volunteers
- 475 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Parkinson Disease
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
- Trial name
- NCT04571164
- Testing
- LY03003(Rotigotine,extended-release microspheres)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Luye Pharma Group Ltd.
Mild Cognitive Impairment (MCI), Parkinson Disease (PD)
A Study of CST-2032 in Subjects With Cognitive Impairment
This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.
- Trial name
- NCT05033912
- Sponsor
- CuraSen Therapeutics, Inc.
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Advanced Parkinson's Disease
Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
This study is a non-interventional post-marketing observational study (PMOS) of participants with advanced Parkinson's disease (PD) treated with Duodopa/Duopa in a routine clinical setting.
- Trial name
- DUOGLOBE (NCT02611713)
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 213 people
- Sponsor
- AbbVie
Treatment of Depression in Adults With Parkinson's Disease (PD)
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
- Trial name
- NCT03482882
- Testing
- Pimavanserin
- Where
- 21 sites in United States
- Volunteers
- 47 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Parkinson Disease
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
A 28-day phase 2a, double-blind, placebo-controlled (1:1), multi-center study of 20 mg NE3107, twice daily of safety, potential drug-drug interactions, and MDS-UPDRS defined activity in patients with Parkinson's disease .
- Trial name
- NCT05083260
- Testing
- NE3107
- Where
- 16 sites in United States
- Volunteers
- 46 people
- Sponsor
- BioVie Inc.
Carcinoma, Nonsquamous Non-small-cell Lung
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976323
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 1,003 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent…
- Trial name
- NCT05173987
- Testing
- pembrolizumab, carboplatin, paclitaxel
- Where
- 194 sites in United States, Australia and 25 more
- Volunteers
- 280 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive…
- Trial name
- NCT03615326
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 192 sites in United States, Australia and 18 more
- Volunteers
- 738 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)
Evaluate the Safety and Effectiveness of Staged Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD).
- Trial name
- NCT04728295
- Testing
- Exablate 4000
- Where
- 9 sites in United States, Spain and 1 more
- Volunteers
- 50 people
- Sponsor
- InSightec
Parkinson's Disease
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy.
- Trial name
- NCT00399477
- Testing
- rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa
- Volunteers
- 200 people
- Sponsor
- Teva Neuroscience, Inc.
Melanoma
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma.
- Trial name
- NCT03553836
- Testing
- Pembrolizumab
- Where
- 159 sites in United States, Australia and 14 more
- Volunteers
- 976 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.